Literature DB >> 11844955

The neurobiology of tobacco dependence: a commentary.

David J K Balfour1.   

Abstract

This commentary summarises the evidence that nicotine has the pharmacological properties of a psychostimulant drug of dependence. Behaviourally it serves as a reinforcer in self-administration experiments. Within the brain, acute nicotine stimulates the release of dopamine (DA) in the shell of the nucleus accumbens whereas repeated nicotine results in selective sensitization of its effects on DA overflow in the accumbal core. These effects are thought to play a central role in the acquisition of responding for nicotine and the development of associations between delivery of the drug and cues that predict its delivery. These responses, therefore, are thought to be pivotal to its ability to cause dependence. The commentary also emphasises the evidence that cigarette smoke provides a vehicle for nicotine that maximises its addictive potential since it delivers nicotine directly into the lungs and, within 10-15 s, to the brain. For habitual cigarette smokers, this process is repeated frequently and regularly and in the context of many other sensory cues within the smoke that potentially provide additional conditioned reinforcers. This, it is argued, explains the strong addiction that many smokers develop to tobacco smoke. Smoking cessation is also associated with the expression of an abstinence syndrome that can, largely, be attributed to nicotine withdrawal and is also likely to contribute to the maintenance of the habit. The commentary closes with a brief review of the pharmacological mechanisms that may contribute to the efficacy of nicotine replacement therapy and Zyban (bupropion) as aids to smoking cessation. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11844955     DOI: 10.1159/000049362

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  25 in total

1.  Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release.

Authors:  Andrew M Smith; Marharyta Pivavarchyk; Thomas E Wooters; Zhenfa Zhang; Guangrong Zheng; J Michael McIntosh; Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Biochem Pharmacol       Date:  2010-03-25       Impact factor: 5.858

2.  A research agenda for assessing the potential contribution of genomic medicine to tobacco control.

Authors:  Wayne D Hall
Journal:  Tob Control       Date:  2007-02       Impact factor: 7.552

3.  Brand differences of free-base nicotine delivery in cigarette smoke: the view of the tobacco industry documents.

Authors:  G Ferris Wayne; G N Connolly; J E Henningfield
Journal:  Tob Control       Date:  2006-06       Impact factor: 7.552

4.  Smoking and suicidal behaviors in the National Comorbidity Survey: Replication.

Authors:  Ronald C Kessler; Patricia A Berglund; Guilherme Borges; Ruby C Castilla-Puentes; Meyer D Glantz; Savina A Jaeger; Kathleen R Merikangas; Matthew K Nock; Leo J Russo; Paul E Stang
Journal:  J Nerv Ment Dis       Date:  2007-05       Impact factor: 2.254

5.  Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD).

Authors:  Linda P Dwoskin; B Matthew Joyce; Guangrong Zheng; Nichole M Neugebauer; Vamshi K Manda; Paul Lockman; Roger L Papke; Michael T Bardo; Peter A Crooks
Journal:  Biochem Pharmacol       Date:  2007-07-21       Impact factor: 5.858

6.  Angiotensin AT1 and AT2 receptor antagonists modulate nicotine-evoked [³H]dopamine and [³H]norepinephrine release.

Authors:  Vidya Narayanaswami; Sucharita S Somkuwar; David B Horton; Lisa A Cassis; Linda P Dwoskin
Journal:  Biochem Pharmacol       Date:  2013-07-04       Impact factor: 5.858

7.  The Nicotine Dependence Syndrome Scale in Finnish smokers.

Authors:  Ulla Broms; Pamela A F Madden; Andrew C Heath; Michele L Pergadia; Saul Shiffman; Jaakko Kaprio
Journal:  Drug Alcohol Depend       Date:  2006-12-13       Impact factor: 4.492

8.  Substituted heteroaromatic compounds: effect on nicotine self-administration in rats.

Authors:  John R Cashman; Karl Okolotowicz; Matt Cerny; Robert Johnson; Aaron Janowsky; Marc R Azar
Journal:  Psychopharmacology (Berl)       Date:  2012-01-05       Impact factor: 4.530

9.  Introduction of unsaturation into the N-n-alkyl chain of the nicotinic receptor antagonists, NONI and NDNI: effect on affinity and selectivity.

Authors:  Sangeetha P Sumithran; Peter A Crooks; Rui Xu; Jun Zhu; Agripina G Deaciuc; Lincoln H Wilkins; Linda P Dwoskin
Journal:  AAPS J       Date:  2005-08-29       Impact factor: 4.009

Review 10.  Genetics of nicotine dependence and pharmacotherapy.

Authors:  Christina N Lessov-Schlaggar; Michele L Pergadia; Taline V Khroyan; Gary E Swan
Journal:  Biochem Pharmacol       Date:  2007-08-19       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.